Purdue's proposed settlement could be in trouble after it was revealed how much Sacklers profited


It's becoming a little clearer just how much cash the Sackler family raked in from their ownership of Purdue Pharma, the pharmaceutical giant known for making OxyContin and allegedly playing a major role in the opioid epidemic plaguing the United States.
Bankruptcy court filings revealed that Purdue reportedly sent $12 billion or $13 billion in profits to the Sacklers, The Wall Street Journal reports, though it's not clear what years the distribution covered.
The figure is relevant as some states, cities, and tribes are looking to settle lawsuits with Purdue, which has been accused of fueling the opioid crisis through its marketing of OxyContin, while others argue the Sacklers should contribute more than they have agreed to so far. Purdue and the Sacklers deny the allegations about their role in the crisis, but they tentatively struck a deal with some states and local governments, in which the Sacklers would contribute $3 billion toward a potentially $12 billion total settlement.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
The recent revelations are likely to "bolster resistance" to the settlement, however, the Journal reports. "The Sackler family is trying to take advantage of the fact that they've extracted nearly all the money out of Purdue and pushed the carcass of the company into bankruptcy," North Carolina Attorney General Josh Stein said Friday. "That's unacceptable." Read more at The Wall Street Journal.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
How to create a healthy 'germier' home
Under The Radar Exposure to a broad range of microbes can enhance our immune system, especially during childhood
-
George Floyd: Did Black Lives Matter fail?
Feature The momentum for change fades as the Black Lives Matter Plaza is scrubbed clean
-
National debt: Why Congress no longer cares
Feature Rising interest rates, tariffs and Trump's 'big, beautiful' bill could sent the national debt soaring
-
RFK Jr. scraps Covid shots for pregnant women, kids
Speed Read The Health Secretary announced a policy change without informing CDC officials
-
New FDA chiefs limit Covid-19 shots to elderly, sick
speed read The FDA set stricter approval standards for booster shots
-
US overdose deaths plunged 27% last year
speed read Drug overdose still 'remains the leading cause of death for Americans aged 18-44,' said the CDC
-
Trump seeks to cut drug prices via executive order
speed read The president's order tells pharmaceutical companies to lower prescription drug prices, but it will likely be thrown out by the courts
-
RFK Jr. visits Texas as 2nd child dies from measles
Speed Read An outbreak of the vaccine-preventable disease continues to grow following a decade of no recorded US measles deaths
-
Shingles vaccine cuts dementia risk, study finds
Speed Read Getting vaccinated appears to significantly reduce the chances of developing Alzheimer's and other forms of dementia
-
Measles outbreak spreads, as does RFK Jr.'s influence
Speed Read The outbreak centered in Texas has grown to at least three states and Health Secretary Robert F. Kennedy Jr. is promoting unproven treatments
-
RFK Jr. offers alternative remedies as measles spreads
Speed Read Health secretary Robert F. Kennedy Jr. makes unsupported claims about containing the spread as vaccine skepticism grows